

PTO/SB/26 (09-04)

Approved for use 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION

Docket Number (Optional) 2500-2287.05

In re Application of: Woonza M. RHEE et al.

Application No.: 10/766,104 Filed: January 27, 2004

For: METHOD FOR PREVENTING THE FORMATION OF ADHESION FOLLOWING SURGERY OR INJURY

The owner, Angiotech Biomaterials Corp., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term of any patent granted on pending **reference Patent Application No.** 10/766,095, filed on January 27, 2004, as such term is defined in 35 U.S.C. §§ 154 and 173, and as the term on any patent granted on the **reference patent application** may be shortened by any terminal disclaimer filed prior to the grant of the patent on the pending **reference patent application**. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the **reference patent application** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 and 173 of any patent granted on the **reference patent application**, as the term of any patent granted on the **reference patent application** expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney or agent of record.

August 15, 2005

Date

Earen Canaan, Registration No. 42,382

Typed or printed name and Registration No.

Earen Canaan, Registration No. 42,382

Typed or printed name and Registration No.

Earen Canaan, Registration No. 42,382

Typed or printed name and Registration No.

Earen Canaan, Registration No. 42,382

Typed or printed name and Registration No.

Please charge the terminal disclaimer fee under 37 CFR 1.20(d) to Deposit Account No. 18-0580.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.